The treatment resistant depression (TRD) market is witnessing significant advancements with the development of promising pipeline products. These innovative therapies hold great potential in addressing the unmet needs of patients who do not respond adequately to existing treatments. One such promising product is a novel glutamate receptor modulator that has shown promising results in early...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian